Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, Gastroenterology, 142, 1592, 10.1053/j.gastro.2012.04.001 Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology, 40, 1387, 10.1002/hep.20466 Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038 Loomba, 2013, The global NAFLD epidemic, Nat Rev Gastroenterol Hepatol, 10, 686, 10.1038/nrgastro.2013.171 Wong, 2012, Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography, Gut, 61, 409, 10.1136/gutjnl-2011-300342 Arulanandan, 2015, Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 13, 1513, 10.1016/j.cgh.2015.01.027 Noureddin, 2015, Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma, Clin Liver Dis, 19, 361, 10.1016/j.cld.2015.01.012 Loomba, 2012, Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis, Hepatology, 56, 943, 10.1002/hep.25772 Bazick, 2015, Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD, Diabetes Care, 38, 1347, 10.2337/dc14-1239 Idilman, 2008, Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 28, 200, 10.1111/j.1365-2036.2008.03723.x Loomba, 2009, Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 29, 172, 10.1111/j.1365-2036.2008.03869.x Doycheva, 2014, Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD), Adv Ther, 31, 30, 10.1007/s12325-013-0084-6 Ratziu, 2008, Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial, Gastroenterology, 135, 100, 10.1053/j.gastro.2008.03.078 Ratziu, 2010, Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial, Hepatology, 51, 445, 10.1002/hep.23270 Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326 Aithal, 2008, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis, Gastroenterology, 135, 1176, 10.1053/j.gastro.2008.06.047 Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929 Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X Herman, 2006, Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects, J Clin Pharmacol, 46, 876, 10.1177/0091270006289850 Ferre, 2010, Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c, Diabetes Obes Metab, 12, 83, 10.1111/j.1463-1326.2010.01275.x Tremblay, 2011, Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes, Diabetes Obes Metab, 13, 366, 10.1111/j.1463-1326.2011.01362.x Monami, 2012, DPP-4 inhibitors and lipids: systematic review and meta-analysis, Adv Ther, 29, 14, 10.1007/s12325-011-0088-z Giampietro, 2013, Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes, Drug Des Devel Ther, 7, 99 Iwasaki, 2012, Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin, Hepatogastroenterology, 59, 1522 Yilmaz, 2012, Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis, Acta Gastroenterol Belg, 75, 240 Kim, 2013, Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography, Radiology, 268, 411, 10.1148/radiol.13121193 Loomba, 2014, Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study, Hepatology, 60, 1920, 10.1002/hep.27362 Loomba, 2015, Heritability of hepatic fibrosis and steatosis based on a prospective twin study, Gastroenterology, 149, 1784, 10.1053/j.gastro.2015.08.011 Loomba, 2016, Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study, Am J Gastroenterol, 10.1038/ajg.2016.65 Cui, 2016, Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study, Hepatology, 63, 453, 10.1002/hep.28337 Imajo, 2016, Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography, Gastroenterology, 150, 626, 10.1053/j.gastro.2015.11.048 Patel, 2004, Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients, J Hepatol, 41, 935, 10.1016/j.jhep.2004.08.008 Zaman, 2007, Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients, Am J Med, 120, 280, 10.1016/j.amjmed.2006.06.044 Le, 2012, Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial, Hepatology, 56, 922, 10.1002/hep.25731 Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4 Lin, 2015, Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique, Clin Gastroenterol Hepatol, 13, 1337, 10.1016/j.cgh.2014.11.027 Loomba, 2015, Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial), Hepatology, 61, 1239, 10.1002/hep.27647 Zarrinpar, 2015, Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study, Gut, 10.1136/gutjnl-2015-309456 Noureddin, 2013, Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials, Hepatology, 58, 1930, 10.1002/hep.26455 Patel, 2013, Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease, Aliment Pharmacol Ther, 37, 630, 10.1111/apt.12237 Reeder, 2011, Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy, J Magn Reson Imaging, 34, spcone, 10.1002/jmri.22775 Permutt, 2012, Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD, Aliment Pharmacol Ther, 36, 22, 10.1111/j.1365-2036.2012.05121.x Reeder, 2013, Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis, Hepatology, 58, 1877, 10.1002/hep.26543 Cui, 2015, Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study, Aliment Pharmacol Ther, 41, 1271, 10.1111/apt.13196 Doycheva, 2016, Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE, Aliment Pharmacol Ther, 43, 83, 10.1111/apt.13405 Chen, 2011, Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography, Radiology, 259, 749, 10.1148/radiol.11101942